InflaRx N.V (IF0) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InflaRx N.V (IF0) has a cash flow conversion efficiency ratio of -0.113x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.71 Million ≈ $-5.50 Million USD) by net assets (€41.56 Million ≈ $48.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see InflaRx N.V stock valuation for the company's overall valuation and market capitalisation.
InflaRx N.V - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how InflaRx N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data.
InflaRx N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InflaRx N.V ranked by their cash flow conversion efficiency. Explore cash flow quality index of InflaRx N.V to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Emmerson Resources Ltd
AU:ERM
|
-0.329x |
|
Limes Schlosskliniken AG
XETRA:LIK
|
0.135x |
|
Gs Global
KO:001250
|
-0.169x |
|
Fountaine Pajo
PA:ALFPC
|
0.162x |
|
KNJ Co. Ltd
KQ:272110
|
0.014x |
|
GOLFZON Co. Ltd
KQ:215000
|
0.052x |
|
ABC Taiwan Electronics
TWO:3236
|
0.057x |
|
KNOTUS Co.Ltd
KQ:278650
|
-0.083x |
Annual Cash Flow Conversion Efficiency for InflaRx N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of InflaRx N.V from 2016 to 2025. View InflaRx N.V share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €41.56 Million ≈ $48.58 Million |
€-35.31 Million ≈ $-41.29 Million |
-0.850x | -7.48% |
| 2024-12-31 | €61.42 Million ≈ $71.80 Million |
€-48.56 Million ≈ $-56.77 Million |
-0.791x | -114.48% |
| 2023-12-31 | €102.58 Million ≈ $119.93 Million |
€-37.81 Million ≈ $-44.21 Million |
-0.369x | +3.49% |
| 2022-12-31 | €88.35 Million ≈ $103.29 Million |
€-33.74 Million ≈ $-39.45 Million |
-0.382x | -0.68% |
| 2021-12-31 | €105.28 Million ≈ $123.08 Million |
€-39.94 Million ≈ $-46.69 Million |
-0.379x | +19.14% |
| 2020-12-31 | €77.86 Million ≈ $91.03 Million |
€-36.53 Million ≈ $-42.70 Million |
-0.469x | -16.34% |
| 2019-12-31 | €107.15 Million ≈ $125.27 Million |
€-43.20 Million ≈ $-50.51 Million |
-0.403x | -183.28% |
| 2018-12-31 | €151.39 Million ≈ $176.99 Million |
€-21.55 Million ≈ $-25.19 Million |
-0.142x | -39.89% |
| 2017-12-31 | €119.43 Million ≈ $139.63 Million |
€-12.15 Million ≈ $-14.21 Million |
-0.102x | -152.36% |
| 2016-12-31 | €-25.69 Million ≈ $-30.03 Million |
€-4.99 Million ≈ $-5.84 Million |
0.194x | -- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinic… Read more